The company will also participate in a panel presentation at the World Orphan Medicines Congress highlighting the role of genome sequencing in advancing precision medicine.
STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) — GeneDx (Nasdaq: WGS), a leader in enabling improved health outcomes through genomic insights, today announced that it is a leading healthcare technology company in the pharmaceutical industry. Announced strategic partnership with Komodo Health. industry. This new partnership will increase access to GeneDx's extensive anonymized rare disease dataset. This dataset is currently available through Komodo Health's MapEnhance product, which includes data from over 500,000 exomes, allowing biopharmaceutical companies to inform drug pipelines and improve clinical trials. gain access to genetic insights that can help accelerate Registration.
“The partnership between GeneDx and Komodo Health is a milestone in advancing the understanding of rare diseases and related drug development,” said Melanie Duquette, GeneDx Chief Growth Officer. “Investment in drug discovery for rare diseases continues to grow, and by making our data more easily accessible to the companies at the forefront of these discoveries, we are expanding access to life-changing treatments. We want to accelerate it.”
GeneDx's rare disease datasets are recognized for their depth and accuracy, making them a valuable resource for biopharmaceutical companies seeking to identify new therapeutic targets and optimize clinical trial designs. As an expert partner of MapEnhance, GeneDx's rich repository of anonymized genetic data will now be accessible through Komodo's end-to-end platform, helping companies unlock deeper insights into genetically based diseases and discover new We help accelerate breakthrough treatments.
“By combining the power of GeneDx's genetic intelligence with Komodo's comprehensive, longitudinal patient trajectory perspective, we aim to advance precision medicine and pave the way to more personalized treatments for patients. It will be a huge acceleration for businesses,” said General Brad Kelly. Komodo Health, MapEnhance Manager: “We are excited to welcome GeneDx to his MapEnhance family and help our customers more quickly uncover the complex genetic basis of disease.”
GeneDx continues to demonstrate its value to biopharmaceutical companies through its participation in the World Orphan Drug Congress, April 23-25 in Boston. At the conference, GeneDx will present a panel titled “Enabling Precision Medicine as a Standard of Care,” which will explore how genomic information can advance precision medicine from the laboratory, biopharmaceutical, and parent perspectives. consider different perspectives. Additional panel details:
Realizing precision medicine as standard treatment
Thursday, April 25:1:00-1:40pm
Hall C, Theater 1: Diagnostic Truck
Speaker:
-
Amanda Singleton, MPH, ScM, CGC, Biopharma Partnership, GeneDx
-
Ben Willis, Director of Business Excellence, Egetis Therapeutics US
-
Effie Parks, Podcast Host and Partnerships Director, Once Upon a Gene – CTNNB1
GeneDx provides customized solutions for biopharmaceutical partners across all stages of the drug development cycle, from early research and development to clinical trial recruitment.
-
Search: Find clinicians and patients using GeneDx's unparalleled datasets.
-
Explore: Use clinical genomic insights to inform the drug discovery process and provide market insights for cohort builders.
-
Partners: Collaborative programs to increase access, speed diagnosis, and patient discovery
To learn more about opportunities to partner with GeneDx, please visit our website or stop by the GeneDx booth #613 at the World Orphan Drug Congress.
About GeneDx
At GeneDx (Nasdaq: WGS), we believe everyone has the right to personalized and targeted healthcare, and it all starts with genetic diagnosis. Powered by the world's largest rare disease dataset, our industry-leading exome and genomic testing transforms complex genomic data into clinical answers, guides personalized care plans, and accelerates drug discovery. , improve the efficiency of healthcare systems. It all starts with his one test. For more information, visit www.genedx.com and connect with us on LinkedIn, Facebook, X, and Instagram.
GeneDx Investor Information Contact: Investors@GeneDx.com
GeneDx Media Contact: Press@GeneDx.com
About Komodo Health
Komodo Health combines real-world data with the industry's most complete view of patient encounters, enterprise software and machine learning that connect the dots between individual patient journeys and large-scale health outcomes. and a technology platform company creating new standards in analytics. Komodo helps customers unearth patient-centric insights at scale across life sciences, payers, providers, and developers. This means combining clinical data with advanced algorithms and AI-powered software solutions to inform decision-making, close gaps in care, address disease burden, and help companies create more cost-effective, value-driven solutions. We will help you build your medical system. For more information, please visit Komodohealth.com.
Media Contact: media@komodohealth.com
